Jump to content

FDA (finally) approves tarceva for late stage maint..


Recommended Posts

I'm pleased to let you know Genentech just issued a press release announcing that Tarceva has received FDA approval for use as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

More details, including the exact approved indication, are included in the press release attached below. You can also view it at

http://www.gene.com/gene/news/press-rel ... l&id=12727

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.